EUVIMEDEUVIMED entdecken
Crossref

Cost-effectiveness of drug therapies in benign prostatic hyperplasia in the University of Ilorin Teaching Hospital, Nigeria

H.B. Giwa, A.A. Ajulo, O.M. Aiyelero, A. Giwa, O.M. Jamiu, A.O. Shittu, S. Njinga, A. Abduli

Journal of Pharmaceutical Sciences and Pharmacy Practice · 2024 · 13 (1&2) · 9-15

DOI: 10.52968/15608473 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Pharmaceutical Sciences and Pharmacy Practice, 2024. Verfasst von H.B. Giwa und 7 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

A growing global population and an aging demographic necessitate enhanced strategies for the prevention and management of Benign Prostatic Hyperplasia (BPH), given its projected rise in prevalence. Methodology: A sample size of 405 patients, along with their corresponding case notes, was selected from the total population of patients diagnosed with benign prostatic hyperplasia (BPH). A drug utilization study was conducted through a one-year retrospective review (January 2022 to December 2022) of the case notes. The EuroQol 5-Dimensions 5-Level questionnaire (EQ-5D-5L) was used to determine the effectiveness of treatment options based on quality-adjusted life years (QALYs). Cost-effectiveness was expressed as cost per QALY, measured against World Health Organization (WHO) cost- effectiveness thresholds.

Results

Two hundred and ten of the selected cases were placed on Tamsulosin monotherapy (51.9%), 165 (40.7%) on Tamsulosin + Dutasteride, 15 (3.7%) on Tamsulosin + Silodosin, and 15 (3.7%) on Tamsulosin + Finasteride. The average cost and effectiveness (QALY) were as follows: Tamsulosin – $52.6 (4.2597); Tamsulosin + Dutasteride – $249.42 (4.3182); Tamsulosin + Silodosin – $370.43 (3.6684); and Tamsulosin + Finasteride – $518.61 (4.3640). There was a statistically significant difference in the effectiveness of the treatment options. When compared with Tamsulosin, the following Incremental Cost-Effectiveness Ratios (ICERs) were observed: $3363.59/QALY for Tamsulosin + Dutasteride, $3046.79/QALY for Tamsulosin + Finasteride, and Tamsulosin + Silodosin was less cost-effective (dominated). These ICERs were robust under sensitivity analysis.

Conclusions

In the Nigerian healthcare system, Tamsulosin + Dutasteride and Tamsulosin + Finasteride were more cost-effective than the other identified treatment options.

Zitieren

APA

Giwa, H., Ajulo, A., Aiyelero, O., Giwa, A., Jamiu, O., Shittu, A., Njinga, S., & Abduli, A. (2024). Cost-effectiveness of drug therapies in benign prostatic hyperplasia in the University of Ilorin Teaching Hospital, Nigeria. Journal of Pharmaceutical Sciences and Pharmacy Practice, 13(1&2), 9-15. https://doi.org/10.52968/15608473

Vancouver

Giwa H, Ajulo A, Aiyelero O, Giwa A, Jamiu O, Shittu A, et al. Cost-effectiveness of drug therapies in benign prostatic hyperplasia in the University of Ilorin Teaching Hospital, Nigeria. Journal of Pharmaceutical Sciences and Pharmacy Practice. 2024;13(1&2):9-15. doi:10.52968/15608473

BibTeX
@article{Giwa2024,
  author = {Giwa, H.B. and Ajulo, A.A. and Aiyelero, O.M. and Giwa, A. and Jamiu, O.M. and Shittu, A.O. and Njinga, S. and Abduli, A.},
  title = {Cost-effectiveness of drug therapies in benign prostatic hyperplasia in the University of Ilorin Teaching Hospital, Nigeria},
  journal = {Journal of Pharmaceutical Sciences and Pharmacy Practice},
  year = {2024},
  volume = {13},
  number = {1&2},
  pages = {9--15},
  doi = {10.52968/15608473}
}
Kostenlos starten →